| American Heart Association Late-Breaking Clinical Trial... |
|
... wire-USNewswire/ -- Acutely ill heart attack patients who received both aspirin and a new reversible oral anti-platelet medication had fewer cardiac events than patients... More »
|
|
Entrepreneur.com - Nov. 15, 2009
|
| PLATO: Ticagrelor benefits seen in STEMI subanalysis |
|
MedWire News: The investigational oral antiplatelet therapy ticagrelor significantly reduces the risk for major cardiovascular events and all-cause mortality compared with... More »
|
|
MedWire News - Nov. 16, 2009
|
| AstraZeneca Drug Beats Plavix for Myocardial Infarction |
|
An experimental anti-clotting drug being developed by AstraZeneca was shown to be more effective than Plavix® (clopidogrel) in treating heart patients who have the most... More »
|
|
EMax Health - Nov. 15, 2009
|
| AHA: Patients Suffering STEMI Fare Better with Ticagrelor... |
|
ORLANDO -- The investigational platelet aggregation inhibitor ticagrelor appeared to produce better outcomes in patients with high-risk, acute coronary syndromes than... More »
|
|
MedPage Today - Nov. 15, 2009
|
| BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in... |
|
Let the jobs come to you! : Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI) AstraZeneca today announced results... More »
|
|
PharmiWeb - Nov. 16, 2009
|
| PLATO: Ticagrelor decreased mortality from CV, MI, stroke... |
|
Treatment with ticagrelor, an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor (P2Y12), significantly reduced mortality associated with... More »
|
|
Hemonctoday - Nov. 16, 2009
|
| New Antiplatelets vs. Clopidogrel: Ticagrelor Hits,... |
|
ORLANDO, FL—It was a good-news, bad-news day for novel antiplatelet agents in patients with ST-segment elevation myocardial infarction (STEMI) and acute coronary syndromes... More »
|
|
TCTMD.com - Nov. 16, 2009
|